Seeking Alpha

moshakes

moshakes
Send Message
View as an RSS Feed
View moshakes' Comments BY TICKER:
Latest  |  Highest rated
  • Inovio - Dilution And Catalysts Make It A Promising Short [View article]
    You got burned shorting Tsla, Amzn and now Ino. Definitely something wrong with your DD Amit. And of course you have not responded to any of the comments here.
    Sep 10 11:52 AM | 6 Likes Like |Link to Comment
  • 5 Reasons Why I'm Short Tesla [View article]
    Hows shorting TSLA going so far?
    Sep 5 11:12 AM | Likes Like |Link to Comment
  • 6 Reasons ImmunoCellular Therapeutics Is One Of The Best Risk Vs. Rewards In The Market [View article]
    Thanks for the article Joe, very well written!
    Aug 7 01:00 PM | 1 Like Like |Link to Comment
  • Inovio Overextended At $2? [View article]
    From InO's web site:

    - Potentially game-changing phase II efficacy data from lead program in 1Q 2014
    - Advancing discussions with large pharmaceutical companies regarding partnerships
    - Almost $50M in non-dilutive third party R&D grants and expenditures since 2009; operating capital through 2014
    - Recently recognized with Vaccine Industry Excellence Awards for Best Therapeutic Vaccine (for HPV-associated diseases) and Best Early Stage Biotech Company at World Vaccine Congress.
    -Synthetic DNA vaccines with proprietary delivery technology targeting diseases with multi-billion-dollar markets; designed to extend the powerful capabilities but overcome limitations of conventional vaccines
    - Best-in-class T-cell immune responses displaying killing effect against target cells – designed to fight cancers, HIV, hepatitis and other diseases requiring treatment
    - Universal antibody immune responses to protect against constantly changing viruses such as influenza
    - Favorable safety profile with no serious adverse events in hundreds of subjects to date
    - Vaccine market expected to reach $52 billion by 2016, up from $13 billion in 2007
    - Dominant global patent position
    - Management team and advisors are leaders in the world of vaccines and DNA vaccines
    Aug 7 07:27 AM | 3 Likes Like |Link to Comment
  • Inovio Overextended At $2? [View article]
    Basically, the author who is short, totally mischaracterized the company. He ignored everything the company has going for it today, it's Phase II HPV trial, the HIV DNA vaccine, the universal influenza vaccine, the universal cancer vaccine etc... and talked about things that existed years ago, the electrochemotherapy and immunotherapy treatments that have been discontinued. The thing that is so hard to believe is that almost everything he wrote has nothing to do with the company that Inovio is today. His intent was to throw as much misinformation in there so that if you didn't understand the company yourself, you leave totally confused and with a picture of the company that is everything other than what Inovio is about. It is really sad people act on this kind of misinformation.
    Aug 6 10:35 PM | 5 Likes Like |Link to Comment
  • Inovio Overextended At $2? [View article]
    Very well Said markbuti.
    Aug 6 09:29 PM | 1 Like Like |Link to Comment
  • Inovio Overextended At $2? [View article]
    If I was trying to knock IBM as a company and I told you that it started as a company that manufactured a wide range of products, including employee time-keeping systems, weighing scales, automatic meat slicers, coffee grinders, and punched card equipment, would you take me seriously if that was part of my argument to knock IBM? That is how IBM started. How many companies start off doing one thing and evolve to the point where they find there nitch, focus on it and then excel? There are thousands like that. I guess for Inovio, that is not acceptable. Even though what they are doing now has got the attention of large pharma and major scientific publications, the NIH, the defense department, etc…. Let's just ignore the success they are having now and instead focus on something one of the past companies that merged with other companies to create today's Inovio did that was not successful. I guess that is what I would do if I was willing to misrepresent the facts to accomplish my investment objective like the author of the article.
    Aug 6 09:28 PM | 12 Likes Like |Link to Comment
  • Can you look at Ino plz!
    Jul 31 05:08 PM | Likes Like |Link to Comment
  • 2 Undervalued Immunotherapy Picks [View article]
    Oncs great company with bright Future!!! Good Article.
    Apr 15 07:07 AM | 1 Like Like |Link to Comment
COMMENTS STATS
9 Comments
34 Likes